Non-Invasive Glucose Monitoring: Which Technologies Are Closest?

The Holy Grail of Diabetes Management

For decades, people with diabetes have dreamed of a device that measures blood glucose without any needles, lancets, or skin penetration whatsoever. No finger pricks. No sensor insertions. Just a watch, a ring, or a handheld scanner that reads glucose levels instantly and continuously. The technology has been "just a few years away" for so long that many patients have grown justifiably skeptical. So where do things actually stand in 2025?

The honest answer: we are closer than ever — but true clinical-grade, fully non-invasive glucose monitoring still does not exist with the accuracy needed for insulin dosing decisions. Here is a clear-eyed breakdown of the leading technologies and their real-world status.

The Main Technologies in Development

1. Near-Infrared (NIR) Spectroscopy

NIR spectroscopy works by shining infrared light through skin tissue and analyzing how glucose absorbs that light. It is arguably the most studied non-invasive approach. The challenge is that water, fat, hemoglobin, and other tissue components all interfere with the signal, making accurate glucose isolation extraordinarily difficult.

Samsung has been the most high-profile company pursuing NIR spectroscopy in a wearable form, announcing it as a target feature for Galaxy Watch hardware. However, as of 2025, Samsung has not released a medically validated non-invasive glucose monitoring function on any consumer device. The sensors on current Galaxy Watch models measure other biometrics, not glucose. Samsung has been transparent that further research and regulatory clearance are required before any glucose feature could launch.

2. Raman Spectroscopy

Raman spectroscopy uses a different light-scattering technique that can be more specific to glucose molecules. Google's parent company Alphabet explored this approach through its Verily life sciences division, though progress has been slow and no consumer product has emerged. Several academic institutions continue publishing research in this area, with studies showing promise in controlled laboratory settings that has not yet translated consistently to real-world accuracy across diverse skin tones, temperatures, and hydration levels.

3. Microwave and Radio Frequency (RF) Sensing

RF-based approaches send electromagnetic waves through tissue and measure dielectric changes correlated with glucose. Israeli company Hagar (formerly GlucoMe spinout technology) and Rockley Photonics have explored photonic chip-based biosensing that combines multiple spectroscopy approaches. Rockley Photonics went public via SPAC and has faced significant financial turbulence, but its sensor platform — which measures multiple biomarkers including glucose proxies — remains a technical milestone in miniaturizing photonic sensing into a wrist-worn form factor. Rockley has been clear that its glucose measurement is an estimation, not a clinically validated direct glucose reading.

4. Fluorescence-Based Optical Sensors

Some researchers are working on minimally invasive — rather than fully non-invasive — optical approaches. These involve implanting a small fluorescent sensor just under the skin that is then read optically through the skin without any blood draw. Profusa, acquired by Biolinq, has been developing a tissue-integrated biosensor using this principle. Biolinq's approach involves a micro-sensor patch that sits in the interstitial fluid just below skin surface, read by a wearable reader. While technically minimally invasive rather than fully non-invasive, it represents a significant reduction in the burden of traditional CGM sensor insertion.

5. Transdermal Electrochemical Sensing

PKvitality's K'Watch Glucose, developed in partnership with STMicroelectronics, uses micro-needle biosensors embedded in a watch strap that painlessly penetrate the outer skin layer to access interstitial fluid. This device underwent clinical evaluation in Europe and represents perhaps the most mature near-market non-invasive-feeling technology, even though it technically involves micro-penetration. Regulatory discussions with the FDA and CE marking efforts were ongoing as of early 2025.

Current Status (2025)

As of 2025, no fully non-invasive glucose monitoring device has received FDA clearance or CE marking for clinical diabetes management. Consumer wearables claiming glucose insights — including certain smartwatch features available in some Asian markets — have not demonstrated the accuracy required for insulin dosing. The FDA has specifically warned consumers against relying on smartwatch glucose readings for treatment decisions.

The current gold standard for continuous glucose monitoring remains sensor-based CGM systems such as the Dexcom G7, Abbott FreeStyle Libre 3, and Medtronic Simplera — all of which require a small sensor filament inserted under the skin. These are available now and represent genuinely transformative technology. Patients can explore CGM supplies and current monitoring options at mdsdiabetes.com.

Why Is This So Hard?

Glucose is present in blood and interstitial fluid at concentrations of roughly 70–180 mg/dL in a healthy range — a relatively small signal that must be detected through layers of skin, fat, and other biological material that vary enormously between individuals, body sites, skin tones, and even time of day. Any non-invasive sensor must be accurate enough to guide clinical decisions — meaning errors of more than 15–20% could lead to dangerous insulin overdosing or missed hypoglycemia. That accuracy bar is extremely high.

Timeline: When Might This Be Available?

Realistic projections from industry analysts and researchers suggest:

• 2025–2026: Micro-needle approaches (like PKvitality) potentially reaching CE marking in Europe; continued FDA engagement for others
• 2026–2028: First generation minimally invasive optical sensors (Biolinq-type) potentially reaching broader markets if clinical validation succeeds
• 2028–2032+: Truly non-invasive optical devices achieving clinical-grade accuracy — optimistic but plausible if current technical hurdles are resolved

Patients interested in following clinical trials can search ClinicalTrials.gov using terms like "non-invasive glucose monitoring" to find enrolling studies.

What This Means for Patients

If you are managing diabetes today, the most impactful decision you can make is adopting current-generation CGM technology, which has robust clinical evidence behind it and dramatically improves time-in-range, reduces hypoglycemia, and improves quality of life. Do not delay good diabetes management waiting for a non-invasive solution that remains years from clinical availability.

That said, the field is genuinely progressing. The technologies described above are real, the science is advancing, and major companies including Apple (rumored long-term R&D), Samsung, and multiple medical device startups are investing heavily. The question is no longer "if" but "when" — and the honest answer is that clinical-grade non-invasive monitoring is likely still several years from your wrist.

Stay informed, keep watching this space, and in the meantime work with your diabetes care team to optimize the excellent monitoring tools that exist right now.